| WB | 1/500-1/1000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | OATPJ; OATP-J; OATP5A1; OATPRP4; OATP-RP4; SLC21A15 |
| Entrez GeneID | 81796 |
| WB Predicted band size | Calculated MW: 92 kDa; Observed MW: 92 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse |
| Immunogen | Recombinant protein of human SLCO5A1 |
| Formulation | Purified antibody in TBS with 0.05% sodium azide,0.05%BSA and 50% glycerol. |
+ +
以下是关于SLCO5A1抗体的3篇参考文献示例(注：部分文献为假设性描述，实际研究可能有限)：
1. **文献名称**: "SLCO5A1 as a novel biomarker in colorectal cancer: Expression profiling and validation via immunohistochemistry"
**作者**: Zhang Y, et al.
**摘要**: 该研究通过免疫组化(使用特异性SLCO5A1抗体)分析了SLCO5A1在结直肠癌组织中的表达水平，发现其高表达与患者预后不良相关，提示其可能作为癌症治疗的潜在靶点。
2. **文献名称**: "Functional characterization of SLCO5A1 in cellular lipid transport using CRISPR/Cas9 and antibody-based protein detection"
**作者**: Müller J, et al.
**摘要**: 研究利用CRISPR/Cas9敲除SLCO5A1基因，并通过Western blot(使用商业化SLCO5A1抗体)验证蛋白缺失，发现该基因缺失导致细胞内脂质转运能力下降，揭示了其在脂代谢中的关键作用。
3. **文献名称**: "SLCO5A1 genetic variants and protein expression in inflammatory bowel disease"
**作者**: Chen L, et al.
**摘要**: 该研究通过ELISA和免疫荧光(基于SLCO5A1抗体)检测炎症性肠病患者肠道组织中的SLCO5A1蛋白水平，发现其表达与疾病严重程度呈负相关，提示其可能具有抗炎保护功能。
**注**：SLCO5A1研究相对较少，以上文献为示例性质，实际文献需通过PubMed、Google Scholar等平台以关键词“SLCO5A1 antibody”或“SLCO5A1 protein expression”检索确认。
The SLCO5A1 (Solute Carrier Organic Anion Transporter Family Member 5A1) gene encodes a transmembrane protein belonging to the organic anion-transporting polypeptide (OATP) family. These transporters facilitate the cellular uptake of various endogenous compounds, such as hormones (e.g., thyroid hormones, steroids), and exogenous substances, including drugs. SLCO5A1. also known as OATP5A1. is expressed in multiple tissues, including the liver, kidneys, and brain, though its specific physiological roles and substrates remain under investigation.
Antibodies targeting SLCO5A1 are essential tools for studying its expression, localization, and function in both normal and pathological contexts. They are widely used in techniques like Western blotting, immunohistochemistry, and immunofluorescence to analyze protein levels and tissue distribution. Research has linked SLCO5A1 dysregulation to diseases such as cancer, where altered expression may influence tumor progression or drug resistance. For example, studies suggest its potential role in modulating chemotherapy uptake in cancer cells.
However, challenges persist, including ensuring antibody specificity due to structural similarities among OATP family members. Commercial SLCO5A1 antibodies vary in reliability, requiring validation via knockout controls or siRNA knockdowns. Despite these hurdles, SLCO5A1 antibodies remain critical for elucidating the protein’s biological significance and therapeutic potential, particularly in personalized medicine and drug delivery research.
×
